Post-earnings recap
Reported
Mon, Apr 29, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics is still in a developmental phase, with no revenue reported and a significant loss per share. The stock reacted negatively, dropping 1.8%, likely due to the lack of guidance and clarity on future financial performance. Investors may be cautious as the company continues to focus on its research initiatives without immediate financial returns.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.93 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their research and development efforts. However, they did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline of therapies.